Abstract
In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating IDH-mutant glioma. Lastly, we summarize the emerging therapeutic targets that can potentially be used in combination with TMZ.
Keywords:
IDH-mutant glioma; TMZ; combination therapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents, Alkylating / adverse effects
-
Antineoplastic Agents, Alkylating / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / genetics*
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / enzymology
-
Brain Neoplasms / genetics
-
Brain Neoplasms / pathology
-
Cell Line, Tumor
-
Clinical Trials as Topic
-
Drug Resistance, Neoplasm
-
Genetic Predisposition to Disease
-
Glioma / drug therapy*
-
Glioma / enzymology
-
Glioma / genetics
-
Glioma / secondary
-
Humans
-
Isocitrate Dehydrogenase / genetics*
-
Mutation*
-
Neoplasm Recurrence, Local
-
Phenotype
-
Temozolomide / adverse effects
-
Temozolomide / therapeutic use*
-
Treatment Outcome
-
Xenograft Model Antitumor Assays
Substances
-
Antineoplastic Agents, Alkylating
-
Biomarkers, Tumor
-
Isocitrate Dehydrogenase
-
Temozolomide